Clinical trial
Meta-Iodobenzylguanidine (123I mIBG) Scintigraphy in Patients Being Evaluated…
NCT00126412 · GE Healthcare, Industry · Completed
Key facts
| NCT number | NCT00126412 |
|---|---|
| Title | Meta-Iodobenzylguanidine (123I mIBG) Scintigraphy in Patients Being Evaluated for Phaeochromocytoma or Neuroblastoma |
| Official title | An Open-Label, Multicentre, Phase 3 Scintigraphy Study Assessing 123I-mIBG Uptake in Subjects Being Evaluated for Phaeochromocytoma or Neuroblastoma |
| Lead sponsor | GE Healthcare, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Pheochromocytoma, Neuroblastoma |
| Intervention type | Drug |
| Interventions | 123I-mIBG (meta-iodobenzylguanidine) |
| Enrollment | 251 |
| Start date | Aug 2, 2005 |
| Primary completion | Sep 27, 2006 |
| Completion | Sep 27, 2006 |
| First posted | Aug 4, 2005 |
| Last update posted | May 31, 2019 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: